» Articles » PMID: 31022523

Natural Products in Licorice for the Therapy of Liver Diseases: Progress and Future Opportunities

Overview
Journal Pharmacol Res
Publisher Elsevier
Specialty Pharmacology
Date 2019 Apr 26
PMID 31022523
Citations 89
Authors
Affiliations
Soon will be listed here.
Abstract

Liver diseases related complications represent a significant source of morbidity and mortality worldwide, creating a substantial economic burden. Oxidative stress, excessive inflammation, and dysregulated energy metabolism significantly contributed to liver diseases. Therefore, discovery of novel therapeutic drugs for the treatment of liver diseases are urgently required. Licorice is one of the most commonly used herbal drugs in Traditional Chinese Medicine for the treatment of liver diseases and drug-induced liver injury (DILI). Various bioactive components have been isolated and identified from the licorice, including glycyrrhizin, glycyrrhetinic acid, liquiritigenin, Isoliquiritigenin, licochalcone A, and glycycoumarin. Emerging evidence suggested that these natural products relieved liver diseases and prevented DILI through multi-targeting therapeutic mechanisms, including anti-steatosis, anti-oxidative stress, anti-inflammation, immunoregulation, anti-fibrosis, anti-cancer, and drug-drug interactions. In the current review, we summarized the recent progress in the research of hepatoprotective and toxic effects of different licorice-derived bioactive ingredients and also highlighted the potency of these compounds as promising therapeutic options for the treatment of liver diseases and DILI. We also outlined the networks of underlying molecular signaling pathways. Further pharmacology and toxicology research will contribute to the development of natural products in licorice and their derivatives as medicines with alluring prospect in the clinical application.

Citing Articles

New tetrahydroisoquinolines bearing nitrophenyl group targeting HSP90 and RET enzymes: synthesis, characterization and biological evaluation.

Bakhite E, Hassanien R, Farhan N, Sayed E, Sharaky M BMC Chem. 2025; 19(1):46.

PMID: 39985107 PMC: 11846289. DOI: 10.1186/s13065-025-01399-0.


Congenital intrahepatic portosystemic shunt in 27 children: an experience and treatment strategy of a single centre in China.

Zhang J Front Pediatr. 2024; 12:1428270.

PMID: 39670191 PMC: 11634595. DOI: 10.3389/fped.2024.1428270.


Chinese Herbal Medicines as Natural Alternative Products to Antibiotics in Weaned Piglets through Intestinal Microbiota Regulation.

Wang C, Chung K, Su L, Wu W, Wang P, Lee M Int J Mol Sci. 2024; 25(20).

PMID: 39456815 PMC: 11506844. DOI: 10.3390/ijms252011034.


An In-depth Review on in the Management of Liver Health and Liver Cancer.

Saraswat I, Goel A, Gupta J Anticancer Agents Med Chem. 2024; 25(1):24-34.

PMID: 39225208 DOI: 10.2174/0118715206307964240821051756.


The involvement of the Stat1/Nrf2 pathway in exacerbating Crizotinib-induced liver injury: implications for ferroptosis.

Guo L, Ma J, Xiao M, Liu J, Hu Z, Xia S Cell Death Dis. 2024; 15(8):600.

PMID: 39160159 PMC: 11333746. DOI: 10.1038/s41419-024-06993-z.